Previous 10 | Next 10 |
In an increasingly saturated landscape of immune oncology companies, Affimed presents a new solution through innate NK cell therapies designed to fight relapsed cancers. Affimed’s core technology has garnered corporate interest in the sector, leading to immune oncology partners...
Affimed's wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology. The company's three-pronged approach of testing their products as a monotherapy, NK combo, and...
The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an early-stage study for its lead asset.The presentations from Eli Lilly (LLY), Oncternal Therape...
On Thursday, drugmaker Affimed N.V. (NASDAQ: AFMD) released its earnings report for the fiscal year 2020, which ended on Dec. 31. Investors were not pleased with the company's financial results, however, and its shares fell sharply as a result. Affimed's stock ended the day down by ...
Affimed N.V. (AFMD) Q4 2020 Earnings Conference Call April 15, 2021 08:30 ET Company Participants Alexander Fudukidis - Head, Investor Relations Adi Hoess - Chief Executive Officer Angus Smith - Chief Financial Officer Andreas Harstrick - Chief Medical Officer Denise Mueller - Chief Business ...
Affimed ([[AFMD]] -7.8%) FY results:Revenue of €28.4M (+32.7% Y/Y).Operating Loss: (€34.72M) (-7.23%); Net Loss: (€41.37M) (-27.80%); Loss Per Share: (€0.50) (flat Y/Y).Quick Assets: €146.9M, with anticipated cash runway into 2H...
Gainers: Ardelyx (ARDX) +13%, Liquidia (LQDA) +9%, PPD (PPD) +7%, Inovio Pharmaceuticals (INO) +6%, BiomX (PHGE) +6%.Losers: Zomedica (ZOM) -12%, Affimed (AFMD) -10%, Aesthetic Medical International (AIH) -7%, Galectin Therapeut...
Affimed (AFMD): FY GAAP EPS of -€0.50 misses by €0.48.Revenue of €28.4M (+32.7% Y/Y) beats by €12.81M.Press Release For further details see: Affimed EPS misses by €0.48, beats on revenue
Affimed (AFMD) announces pre-clinical data on its Innate Cell Engager ((ICE)) AFM24 as monotherapy and in combination with adoptively transferred NK cells at AACR Meeting 2021. AFM24 induces NK cell-mediated antibody-dependent cellular cytotoxicity ((ADCC)) against EGFR-expressing tumor cells...
AFM24 induces strong tumor cell killing independent of KRAS mutations AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...